

Form PTO-1594 (Rev. 07/05)
OMB Collection 0651-0027 (exp. 6/30/2008)

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

RECORDATION FORM COVER SHEET TRADEMARKS ONLY

To the Director of the U. S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies):

Axxima Pharmaceuticals AG

- Individual(s)
- General Partnership
- Corporation- State: Munich, Germany
- Other _____
- Association
- Limited Partnership

Citizenship (see guidelines) Germany

Additional names of conveying parties attached? Yes No

3. Nature of conveyance)/Execution Date(s) :

Execution Date(s) August 11 and 17, 2005

- Assignment
- Security Agreement
- Other acknowledgement of asset acquisition
- Merger
- Change of Name

2. Name and address of receiving party(ies)

Additional names, addresses, or citizenship attached? Yes No

Name: GPC Biotech Forschungsgesellschaft mbH

Internal

Address: _____

Street Address: Fraunhoferstrasse 20

City: Martinsried/Munich

State: _____

Country: GERMANY Zip: 82152

- Association Citizenship _____
- General Partnership Citizenship _____
- Limited Partnership Citizenship _____
- Corporation Citizenship Germany
- Other _____ Citizenship _____

If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No
(Designations must be a separate document from assignment)

4. Application number(s) or registration number(s) and identification or description of the Trademark.

A. Trademark Application No.(s)

B. Trademark Registration No.(s)

Reg. No. 2,526,752; Mark: AXXIMA

Reg. No. 2,791,029; Mark: FIREWALLS AGAINST INFECTIONS

Additional sheet(s) attached? Yes No

C. Identification or Description of Trademark(s) (and Filing Date if Application or Registration Number is unknown):

5. Name & address of party to whom correspondence concerning document should be mailed:

Name: Leon R. Yankwich

Internal Address: Yankwich & Associates, P.C.

Street Address: 201 Broadway

City: Cambridge

State: Massachusetts Zip: 02139

Phone Number: 617-374-3700

Fax Number: 617-374-0055

Email Address: LYankwich@yankwich.com

6. Total number of applications and registrations involved:

six (6)

7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$ 240.00

- Authorized to be charged by credit card
- Authorized to be charged to deposit account
- Enclosed

8. Payment Information:

a. Credit Card Last 4 Numbers _____
Expiration Date _____

b. Deposit Account Number 50-0268

Authorized User Name _____

9. Signature:

Signature

August 28, 2006

Date

David G. O'Brien (Reg. No. 46,125)

Name of Person Signing

Total number of pages including cover sheet, attachments, and document:

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

CH \$165.00 500268 2526752

RECORDATION FORM COVER SHEET - TRADEMARK ONLY
 (Additional Sheet - page 2 of 2)

Item 4B: Trademark Registration Numbers - continued:

	<u>Reg. No.</u>	<u>Mark</u>	<u>Date Registered:</u>
3)	2,639,552	SIGNAL TRANSDUCTION FIREWALL	October 22, 2002
4)	2,651,976	>X<	November 19, 2002
5)	2,525,229	A>X<IMA	January 1, 2002
6)	3,128,644	KINATOR	August 15, 2006

Note: (Trademarks 1 and 2 from Cover Sheet are listed again below along with date registered):

1)	2,526,752	AXXIMA	January 8, 2002
2)	2,791,029	FIREWALLS AGAINST INFECTIONS	December 9, 2003

Eingegangen
16. Aug. 2005



GPC biotech

Kanzlei Dr. Fuchsl
GPC Biotech AG, Fraunhoferstr. 20, D-82152 Martinsried

GPC Biotech AG
Postfach 1455
82143 Planegg
Germany
Fraunhoferstrasse 20
82152 Martinsried/München
Germany
Telefon, Name
BV

Dr. Joseph Fuchsl
Rechtanwalt
Königinstr. 26
80539 München

Date
11. Aug. 2005

Re: Asset Purchase Agreement Dated March 2, 2005

Dear Dr. Fuchsl:

As discussed, the purpose of this letter is to confirm the inclusion of certain intellectual property rights in the sale of assets of Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 Munich, Germany ("Axxima").

On March 1, 2005, you were appointed as insolvency receiver for Axxima (see Exhibit A).

You hereby confirm that on March 2, 2005, a sale and purchase of certain assets of Axxima, including the sale and purchase of all intellectual property rights listed in Exhibit B to this letter (the "IP Assets"), was concluded pursuant to an Asset Purchase Agreement ("Agreement") between you as seller (acting as insolvency receiver for Axxima) and Blitz 05-001 GmbH, Munich, Germany ("Blitz") as purchaser. As a result, all IP Assets were thus assigned to Blitz.

GPC Biotech AG hereby represents that on the same day it acquired all shares of Blitz pursuant to a Contribution Agreement, so that Blitz became a wholly-owned subsidiary of GPC Biotech AG.

GPC Biotech AG further represents that effective as of March 2, 2005, Blitz was renamed to become GPC Biotech Forschungsgesellschaft mbH (see Exhibit C).

GPC Biotech AG finally represents that effective as of June 1, 2005 (pending registration at the Munich commercial register), GPC Biotech Forschungsgesellschaft mbH was merged with and into GPC Biotech AG, so that effective as of such date GPC Biotech AG has become a party to the Agreement as a successor in interest, and all assets purchased under the Agreement, including all right, title and interest in and to the IP Assets, are owned directly by, and reside with, GPC Biotech AG.

GPC Biotech AG

Amtsgericht München HRB 119 555
USt-ID-Nr.: DE 190 457 435

Deutsche Bank AG, München (BLZ 700 100 100) Konto-Nr. 189 01 18
IBAN: DE54 7007 0010 0199 0118 00, SWIFT-BIC: DEUTDE33

Dresdner Bank AG, München (BLZ 700 800 00) Konto-Nr. 300 906 300

BAN: DE58 7008 0000 0300 8063 00, SWIFT-BIC: DRESDE33

HypoVereinsbank AG, München (BLZ 700 202 70) Konto-Nr. 272 66 45

IBAN: DE20 7002 0270 0002 7266 45, SWIFT-BIC: HYVEDE33

Vorstand:

Prof. Dr. Bernd Seizinger (Vorsitzender des Vorstands)
Dr. Einar Meier,
Dr. Sebastian Meier-Ewert,
Dr. Mirko Scherer

Vorsitzender des Aufsichtsrates:


Prof. Dr. Jürgen Drews

TRADEMARK


REEL: 003380 FRAME: 0620

Please indicate your agreement and acknowledgement of the foregoing by signing where indicated below and returning one fully signed original to my attention at the address indicated. Thank you.

Sincerely,

By: 
Dr. Elmar Maier
Senior Vice President,
Business Development

Date: 11. August 2005

Agreed and acknowledged
By: 
RA Dr. Joseph Füchsl

Date: 17. August 2005




i.v. 
DAVID BANCROFT
VP, Intellectual Property
23rd August 2005

Exhibit A

01-Mär-2005 10:33

RA FLECHSEL

+49 69 338317 5.02/04



Amtsgericht München
- Insolvenzgericht -

Inhaberlestrasse 5, 80097 München
Telefon: 089/3387-06, Fax: 089/3387-2777
Bankverbindung: Gerichtskasse München, Kto.: 3024919, (BLZ 700 500 00)

Geschäftsnummer: 1502 IN 3694/04
(Bitte immer angeben)

München, 1.3.2005

Bescheinigung

In dem Insolvenzverfahren

über das Vermögen der

Accima Pharmaceuticals AG, Max-Lebscho-Platz 32, 81377 München
gesetzlich vertreten durch
Vorstandsmitglied Clive Krückemeyer, Pöcking

Vorstandsmitglied Dr. Gerhard Müller, Krefeld-Fischeln

- Schuldnerin -

ist

Herr Rechtsanwalt Dr. Joseph Fuchs

Königinstr. 26, 80539 München
Telefon: 089/343041
Telefax: 089/338317

zum Insolvenzverwalter bestellt worden.

Handwritten initials
R.F.G.



Handwritten signature

Handwritten initials

Exhibit B

Exhibit 1.2 (1)

1-CDK9

Application #	Publication #	Filing date	Title	Status
EP 03 020 888.8		15-Sep-03	4,6-Disubstituted aminopyrimidine derivatives as effective compounds against infectious diseases	expired
US 60/504,527		22-Sep-03	4,6-Disubstituted aminopyrimidine derivatives as effective compounds against infectious diseases	expired
EP04010308.7		30-Apr-04	Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives	pending
US 60/589,806		30-Apr-04	Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives	pending
PCT/EP2004/010 353		15-Sep-04	Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives	pending

2-R.acid

Application #	Publication #	Filing date	Title	Status
US 60/283,345		13-Apr-01	Human cellular protein glutathione peroxidase-gastrointestinal as target for medical intervention against hepatitis C virus infections	expired
PCT/EP2002/041 67	WO 02/084294	15-Apr-02	HUMAN CELLULAR PROTEIN GASTROINTESTINAL GLUTATHIONE PEROXIDASE AS TARGET FOR MEDICAL INTERVENTION AGAINST HEPATITIS C VIRUS INFECTIONS	nationalized
JP 2002-581997		15-Apr-02	HUMAN CELLULAR PROTEIN GASTROINTESTINAL GLUTATHIONE PEROXIDASE AS TARGET FOR MEDICAL INTERVENTION AGAINST HEPATITIS C VIRUS INFECTIONS	pending
CA 2,443,525	CA 2,443,525	15-Apr-02	HUMAN CELLULAR PROTEIN GASTROINTESTINAL GLUTATHIONE PEROXIDASE AS TARGET FOR MEDICAL INTERVENTION AGAINST HEPATITIS C VIRUS INFECTIONS	pending
EP 02 730 159.7	EP1377833	15-Apr-02	HUMAN CELLULAR PROTEIN GASTROINTESTINAL GLUTATHIONE PEROXIDASE AS TARGET FOR MEDICAL INTERVENTION AGAINST HEPATITIS C VIRUS INFECTIONS	pending
DE 10255861.2		29-Nov-02	Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen	expired

WDC - 137780001 - 22906 v1

US 60/430,367		3-Dec-02	Compounds and substances useful against Hepatitis C Infections	expired
US 10/342,054	US 2003-0180719	14-Jan-03	Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus Infections	pending
DE 10305138.4		7-Feb-03	Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen	expired
US 60/446,246		11-Feb-03	Formulation useful against Hepatitis C virus Infections	expired
US 10/723,719	US 2004-0152073	28-Nov-03	Therapeutic targets for treatment of HCV Infections, methods of treating HCV Infections and compounds useful therefor	pending
PCT/EP2003/13514	WO04/050101	1-Dec-03	Formulations useful against Hepatitis C virus Infections	pending
US 60/578,161		9-Jun-04	Combined Therapies Useful Against Hepatitis C Virus Infections	pending

3-PknG

Application #	Publication #	Filing date	Title	Status
US 60/292,325		22-May-01	Benzo (g) quinoxaline derivatives as effective compounds against infectious diseases	expired
EP 01 112 289.2		18-Jun-01	Benzo (g) quinoxaline derivatives as effective compounds against infectious diseases	expired
US 60/298,902		18-Jun-01	SRPK1 and SRPK2 as targets for medical intervention against HBV Infections	expired
EP01 115 508.2		27-Jun-01	Benzo (g) quinoxaline derivatives as effective compounds against infectious diseases	expired
EP 02 007 923.2		9-Apr-02	4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial Infections	expired
PCT/EP2002/05573	WO 02/094,796	21-May-02	Benzo (g) quinoxaline derivatives as effective compounds against infectious diseases	nationalized
EP03720441.9	EP1492783	9-Apr-03	4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial Infections	pending
US 10/510,791		9-Apr-03	4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial Infections	pending

WRE - 317790001 - 22/004 v2

PCT/EP03/03697	WO 03/084,947	9-Apr-03	4,5,6,7-TETRAHYDROBENZO(B) THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCOBACTERIAL INFECTIONS	nationalized
EP 03020618.3		10-Sep-03	4,7-Dihydro-5H-thieno[2,3c]pyran derivatives and their analogues as effective compounds against infectious and other diseases	expired
US 60/602,608		15-Sep-03	4,7-Dihydro-5H-thieno[2,3c]pyran derivatives and their analogues as effective compounds against infectious and other diseases	expired
US 10/716,591	US 2004-0171603	18-Nov-03	Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor	pending
EP 04004891.0		2-Mar-04	4,7-Dihydro-5H-thieno[2,3]pyran derivatives and their analogues as effective compounds against infectious and other diseases	pending
US 60/551,341		10-Mar-04	4,7-Dihydro-5H-thieno[2,3]pyran derivatives and their analogues as effective compounds against infectious and other diseases	pending
EP 04012814.2		28-May-04	Heterobicyclic compounds as pharmaceutically active agents	pending
US 60/577,043		7-Jun-04	Heterobicyclic compounds as pharmaceutically active agents	pending
PCT/EP04/01016 1		10-Sep-04	Heterobicyclic compounds as pharmaceutically active agents	pending

4-RICK

Application #	Publication #	Filing date	Title	Status
EP04018131.5		30-Jul-04	Pyridinylamines	pending
US 60/598,307		6-Aug-04	Pyridinylamines	pending

5-HCMV

Application #	Publication #	Filing date	Title	Status
PCT/EP03/09039		14-Aug-03	Nitrogen heterocyclic compounds as pharmaceutically active compounds	pending
EP 02 018 357.0		14-Aug-03	Nitrogen heterocyclic compounds as pharmaceutically active compounds	pending

WBE - 21770001 - 229008 v2

008/017

46-203

10/872,645

6-ARK

Application #	Publication #	Filing date	Title	Status
PCT/EP02/14578	WO 03/054228	19-Dec-02	Human cellular protein kinases, metalloproteases and phosphatases as targets for medical intervention against Hepatitis C virus infections	not nationalized
US 60/341,767		21-Dec-01	Human cellular protein kinases, metalloproteases and phosphatases as targets for medical intervention against Hepatitis C virus infections	expired

7-Gleevec

Application #	Publication #	Filing date	Title	Status
EP 01111858.8		16-May-01	Human cellular protein kinases and phosphatases as targets for diagnosis and treatment of prion diseases	expired
US 60/293,528		29-May-01	Human cellular protein kinases and phosphatases as targets for diagnosis and treatment of prion diseases	expired
EP 01117113.0		13-Jul-01	Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases	expired
US 60/305,898		18-Jul-01	Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases	expired
US 10/204,041	US 2003/0176443	16-May-02	Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases	pending
WO 02/093164	PCT/EP2002/05420	10-May-02	PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION	nationalized
EP 02 769 490.0	EP 1395261	16-May-02	Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases	pending
CA 2446939	CA 2446939	16-May-02	Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases	pending
US 60/604,685		17-Aug-04	Pyrimidine derivatives	pending

8-UL97

Application #	Publication #	Filing date	Title	Status
EP 03029038.1		16-Dec-03	Pyrazine derivatives as effective compounds against infectious diseases	expired
US 60/530,612		19-Dec-03	Pyrazine derivatives as effective compounds against infectious diseases	expired

WBE-23779001-22908 v3

PCT/EP2004/014 371		16-Dec-04	Pyrazine derivatives as effective compounds against infectious diseases	pending
-----------------------	--	-----------	---	---------

9-Kinator

Application #	Publication #	Filing date	Title	Status
EP 02 016 840.7		29-Jul-02	Medium and method for enriching, purifying or depleting ATP-binding proteins from a pool of proteins	expired
EP 02 028 888.9		23. Dec 02	Medium and method for enriching, purifying or depleting ATP-binding proteins from a pool of proteins	expired
PCT/EP03/08375	WO04/013633	29-Jul-03	Medium and method for enriching, purifying or depleting ATP-binding proteins from a pool of proteins	nationalized
EP 03766347.3		29-Jul-03	Medium and method for enriching, purifying or depleting ATP-binding proteins from a pool of proteins	pending
US phase of WO 04/013633		29-Jul-03	Medium and method for enriching, purifying or depleting ATP-binding proteins from a pool of proteins	pending
EP 04 003 179.1		12-Feb-04	Medium and method for enriching, nucleotide binding proteins from a pool of proteins	expired

10-HSV

Application #	Publication #	Filing date	Title	Status
PCT/EP2004/011 118		5-Oct-04	Quinazoline derivatives for the treatment of herpesviral infections	pending

11-HCV (non-RA)

Application #	Publication #	Filing date	Title	Status
EP 02015098.7		5-Jul-02	IMIDAZOLE COMPOUNDS AND HUMAN CELLULAR PROTEINS CASEIN KINASE I ALPHA, DELTA AND EPSILON AS TARGETS FOR MEDICAL INTERVENTION AGAINST HEPATITIS C VIRUS INFECTIONS	expired
EP phase of WO 04/005264		7-Jul-03	IMIDAZOLE COMPOUNDS AND HUMAN CELLULAR PROTEINS CASEIN KINASE I ALPHA, DELTA AND EPSILON AS TARGETS FOR MEDICAL INTERVENTION AGAINST	pending

WBE - 21790001 - 229001 v2

Handwritten signature

Handwritten initials

			HEPATITIS C VIRUS INFECTIONS	
PCT/EP03/07286	WO 04/005264	7-Jul-03	IMIDAZOLE COMPOUNDS AND HUMAN CELLULAR PROTEINS CASEIN KINASE I ALPHA, DELTA AND EPSILON AS TARGETS FOR MEDICAL INTERVENTION AGAINST HEPATITIS C VIRUS INFECTIONS	nationalized
US phase of WO 04/005264		7-Jul-03	IMIDAZOLE COMPOUNDS AND HUMAN CELLULAR PROTEINS CASEIN KINASE I ALPHA, DELTA AND EPSILON AS TARGETS FOR MEDICAL INTERVENTION AGAINST HEPATITIS C VIRUS INFECTIONS	pending

12-EnzProd

Application #	Publication #	Filing date	Title	Status
EP 03 010 844.3	EP1477567	15-May-03	Method for recombinant production of mammalian proteins and proteins obtainable by such method	pending
PCT/EP04/00525 05		14-May-04	Method for recombinant production of mammalian proteins and proteins obtainable by such method	pending

13-Pyrido

Application #	Publication #	Filing date	Title	Status
EP04010122.2		28-Apr-04	Pyridopyrimidine derivatives	pending
US 60/581,110		21-Jun-04	Pyridopyrimidine derivatives	pending

14-ROCK

Application #	Publication #	Filing date	Title	Status
EP04031076.1		31 Dec 04	Naphthyridine compounds as ROCK2 inhibitors	pending

FB2 - 2779001 - 229001 v2

Trademarks

Trademark	Appdxma case #	Filing date	Official #	Status
Appdxma	TM001DEP	20. Aug 99	39950841	Registered
Appdxma	TM001US	18. Feb 00	2,526,752	Registered
Appdxma	TM001JP	15. Feb 00	4,438,778	Registered
Appdxma	TM001IR	17. Feb 00	730502	Registered
Appdxma	TM001CT	16. Feb 00	001509660	Registered
STF	TM002DEP	13. Nov 99	39971207	Registered
STF	TM002GB	10. May 00	2232089	Registered
Signal Transduction Firewall	TM003DEP	13. Nov 99	39971208	Registered
Signal Transduction Firewall	TM003US	6. May 00	2,639,552	Registered
Signal Transduction Firewall	TM003GB	10. May 00	2232086	Registered
Signal Transduction Firewall	TM003CT	16. Sep 02	002850550	Registered
Signal Transduction Firewall	TM003JP	22. Oct 02	2002-89221	Registered
>X<	TM004DEP	19. Jan 00	30003466	Registered
>X<	TM004US	9. Jun 00	2,651,976	Registered
>X<	TM004JP	4. Jul 00	4,449,208	Registered
>X<	TM004CT	6. Jun 00	001692995	Registered
A>X<IMA	TM005DEP	19. Jan 00	30003467	Registered
A>X<IMA	TM005CT	6. Jun 00	001692714	Registered
A>X<IMA	TM005IR	8. Jun 00	737688	Registered
A>X<IMA	TM005US	9. Jun 00	2,525,229	Registered
A>X<IMA	TM005JP	4. Jul 00	4,449,209	Registered
FIREWALLS AGAINST	TM006DEP	8. Dec 00	30090034	Registered

WBZ - 3/7/2006 - 22/000 v2

TRADEMARK

REEL: 003380 FRAME: 0629

INFECTIONS				
FIREWALLS AGAINST INFECTIONS	TM006CT	28. May 01	002233856	Registered
FIREWALLS AGAINST INFECTIONS	TM006US	27. Mar 00	78/001204	Registered
FIREWALLS AGAINST INFECTIONS	TM006JP	6. Jun 01	4527995	Registered
KINATOR	TM007CT	14. Jul 03		Pending
KINATOR	TM007US			Pending

Internet domains

Domain
axxima.de
axxima.com
virgena.de
virgena.com

WSE-23779001 - 22906 v1

Virgena

003380

Exhibit C

Handelsregister B des Amtsgerichts München

Abwurf vom 10.3.2005 14:36

Nummer der Firma: HRB 156071

1	2	3	4	5	6	7
Nummer der Eintragung	a) Firma b) Sitz c) Gegenstand des Unternehmens	Grund- oder Stammkapital	a) Allgemeine Verordnungsregelung b) Vertretungsberechtigte und besondere Vertretungsbefugnisse	Prokura	a) Gesellschaftsvertrag / Satzung b) Sonstige Rechtsverhältnisse	a) Tag der Eintragung und Bestätigung b) Bemerkungen
1	a) <u>Bilz 05-001 GmbH</u> b) <u>München</u> c) <u>Verwaltung eigenen Vermögens</u>	25.000,00 EUR	a) Ist nur ein Geschäftsführer bestellt, so vertritt er die Gesellschaft allein. Sind mehrere Geschäftsführer bestellt, so wird die Gesellschaft durch zwei Geschäftsführer oder durch einen Geschäftsführer gemeinsam mit einem Prokuristen vertreten. b) <u>Geschäftsführer:</u> <u>Ulbert, Nicole, München, *07.05.1969</u> <u>einzelvertretungsberechtigter, mit der Befugnis, im Namen der Gesellschaft mit sich im eigenen Namen oder als Vertreter eines Dritten Rechtsgeschäfte abzuschließen.</u>	6	a) Gesellschaft mit beschränkter Haftung Gesellschaftsvertrag vom 02.02.2005.	a) 17.02.2005 Eben b) Gesellschaftsvertrag Bl. 3 SB;
2	a) GPC Biotech Forschungsgesellschaft mbH b) Planegg, Ortsteil Martinsried, Landkreis München c) Forschung, Entwicklung und Anwendung von Technologien und Verfahren zur Studie von biologischem Material, funktionelle Analyse identifizierter Genprodukte und deren kommerzielle Nutzung zur Entwicklung von Diagnostika und pharmazeutischen Produkten sowie Erbringung damit verbundenen Dienstleistungen und Vergabe von Lizenzen.		b) <u>Ausgeschieden:</u> <u>Geschäftsführer:</u> <u>Ulbert, Nicole, München, *07.05.1969</u> Bestellt: Geschäftsführer: Dr. Meier, Markus, München, *28.11.1966 einzelvertretungsberechtigter mit der Befugnis, im Namen der Gesellschaft mit sich im eigenen Namen oder als Vertreter eines Dritten Rechtsgeschäfte abzuschließen. Bestellt: Geschäftsführer: Dr. Meier, Einar, Berlin-Dahlem, *14.12.1965 einzelvertretungsberechtigter mit der Befugnis, im Namen der Gesellschaft mit sich als Vertreter eines Dritten Rechtsgeschäfte abzuschließen. Bestellt: Geschäftsführer: Dr. Scherer, Mirko, München, *09.06.1968 einzelvertretungsberechtigter mit der Befugnis, im Namen der Gesellschaft mit sich als Vertreter eines Dritten Rechtsgeschäfte abzuschließen.		a) Die Gesellschafterversammlung vom 02.03.2005 hat die Änderung der §§ 1 (Firma) 2 (Sitz) sowie 4 (Gegenstand des Unternehmens) und 5 (Stammkapital) der Satzung beschlossen. b) Beschluss Bl. 9 SB; neue Satzung Bl. 9 SB;	a) 10.03.2005 Eben b) Beschluss Bl. 9 SB; neue Satzung Bl. 9 SB;

+ 49 89 8565 2600 ☎
+ 49 89 8565 2610 fax
www.gpc-biotech.com



GPC biotech

GPC Biotech AG
Postfach 1455
82143 Planegg
Germany
Fraunhoferstrasse 20
82152 Martinsried/München
Germany

Verification of translation of Exhibits A and C of letter to Dr. Fuchsl dated 11-August-2005:


VERIFICATION

I, the undersigned, Tobias Wittig, of Fraunhoferstrasse 20, 82152 Martinsried/Munich, Federal republic of Germany, hereby certify that I am conversant with the German and English languages and am a competent translator thereof. I further certify that the following pages are true and accurate English translations of the German court documents listed below:

1. Order of the Munich County Court/Insolvency Division appointing Dr. Joseph Fuchsl as insolvency receiver for the assets of Axxima AG, Munich; and
2. Record of the Commercial Register of the County Court, Munich for March 10, 2005 for German Registered Company No. HRB 156071 (Blitz 05-001 GmbH).

The above items 1 and 2 are English translations of Exhibits A and C, respectively to the letter dated August 11, 2005 captioned "Re: Asset Purchase Agreement Dated March 2, 2005" signed by Dr. Joseph Fuchsl, to which letter these verified translations are appended.

Signed this 27th day of July, 2006.


.....
Tobias Wittig

GPC Biotech AG
Amtsgericht München HRB 119 555
USt-ID-Nr.: DE 190 457 435
Deutsche Bank AG
München (BLZ 700 700 10)
Konto -Nr. 199 01 18

Vorstand:
Prof. Dr. Bernd Seizinger (Vorsitzender des Vorstands)
Dr. Elmar Maier
Dr. Sebastian Meier-Ewert
Dr. Mirko Scherer
Vorsitzender des Aufsichtsrates:

Exhibit A

County Court Munich
- Insolvency Court -

Infanteriestraße 5, 80097 Munich
Phone: 089/5597-06, Facsimile 089/5597-2777
Bank account: Gerichtskasse München, Account No. 3024919, (Routing No. 700 500 00)

Reference No.: 1502 IN 3694/04
(Please always include)

Munich, 1. March 2005

Certificate

In the insolvency proceedings

about the assets of

Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 Munich
legally represented by
Board member Clive Krückemeyer, Pöcking
Board member Dr. Gerhard Müller, Krefeld-Fischeln
- debtor -

Dr. Joseph Fuchsl, attorney-at-law,

Königinstr. 26, 80539 Munich
Phone: 089/343041
Facsimile: 089/338317

has been appointed as insolvency receiver.

Exhibit C

Commercial Register County Court Munich			Call of 10 Mar 2005, 14:36		Company Number: HRB 156071	
Registration No.	a) Company b) Place of business c) Kind of business	Capital stock	a) General representation rule b) Representatives and special power of representation	Commercial Procuration	a) Company agreement / articles b) Other legal relationships	a) Day of registration and confirmation b) Comments
1	2 a) <u>Blitz 05-001 GmbH</u> b) <u>Munich</u> c) <u>Manage own assets.</u>	3 25,000,00 EUR	4 a) If only one manager has been appointed he represents the company alone. If several managers have been appointed, the company will be represented by two managers or by one manager together with a proxy. b) <u>Manager: Liebers, Nicole *07. Jun. 1969</u> has power of sole representation; authorized to close legal transactions in the name of the company with herself in her name or as a representative of a third party	5	6 a) Limited liability company, company agreement dated 02. Feb 2005	7 a) 17. Feb 05 Eben b) Company agreement Bl. 3 SB;
2	a) GPC Biotech b) Forschungsgesellschaft mbH Planegg, District Martinsried, County Munich c) Research, development and use of technologies and procedures for the study of biological material, functional analysis of identified gene products and commercial use of these for the development of diagnostics and pharmaceutical products as well as provision of services connected therewith and to grant licenses.		a) Retired: <u>Manager: Liebers, Nicole *07. Jun. 1969</u> Appointed: <u>Dr. Maier, Markus, Munich, *28. Nov. 1968</u> has power of sole representation; authorized to close legal transactions both in the name of the company and as a representative of a third party b) Appointed: <u>Manager: Dr. Maier, Eimar, Berlin-Dahlem, *14. Dec 1965</u> has power of sole representation; authorized to close legal transactions both in the name of the company and as a representative of a third party c) Appointed: <u>Manager: Dr. Scherer, Mirko, Munich, *9. Jun 1968</u> has power of sole representation; authorized to close legal transactions both in the name of the company and as a representative of a third party		a) The shareholders' meeting on 02. Mar 2005 has decided to change §§ 1 (Company) 2 (Place of business) as well as 4 (Kind of business) and 5 (Capital stock) of the articles.	a) 10. Mar 2005 Eben b) Decision Bl. 8 SB; new articles Bl.9 SB;